A Two-Year Study on the Effects of Nicotine and its Withdrawal on Mood and Sleep

Acute administration of nicotine has beneficial effects on a variety of neurological and psychiatric disorders. The purpose of this study was to determine the long-term effects of transdermal nicotine on sleep and major depression. Under a single blind protocol study where patients initially received nicotine and then switched to placebo. Fourteen non-smoking patients with major depression (Hamilton Rating ≥ 18) served as subjects. Transdermal nicotine (17.5 mg), was administered five days weekly for six months, three days weekly on month 7 and one day per week on month 8. From the 9^th to the 24^th month, once a week a patch without nicotine substituted the nicotine patch. Sleep and depression was assessed throughout. REM sleep latency changed from 32.6 min. to 78.2 min. at the end of the study, wakefulness decreased, slow wave sleep increased throughout the study and a transient decrease of REM sleep duration upon nicotine withdrawal was observed. Hamilton scores went from an initial mean score of 29.7 to a final score of 10.8. The results support the possible therapeutical effects of long-term transdermal nicotine on sleep and mood, with a carryover effect into the withdrawal period, even though, the conclusions should be taken with caution due to the design applied.

Nicotine - Depression - Sleep disorders - REM-latency

References

• 1 Benca R -M, Obermeyer W -H, Thisted R -A, Gillin J -C. Sleep and psychiatric disorders. A meta-analysis.  Arch Gen Psychiat. 1992;  49 651-668
• 2 Berger M, Lund R, Bronisch T, von Zerssen D. REM latency in neurotic and endogenous depression and the cholinergic REM induction test.  Psychiatry Res. 1983;  10 13-23
• 3 Berger M, Riemann D, Höchli D, Spiegel R. The cholinergic rapid eye movement sleep induction test with RS-86.  Arch Gen Psychiat. 1989;  46 421-428
• 4 Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression.  J Clin Psychopharm. 1987;  7 24S
• 5 Borbély A, Tobler I, Loepfe M, Kupfer D -J, Ulrich R -F, Grochocinski V ,. et al . All-night spectral analysis of the sleep EEG in untreated depressives and normal controls.  Psychiat Res. 1984;  12 27-33
• 6 Breslau N, Kilbey M -M, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiological study of young adults.  Am J Psychiat. 1992;  149 464-469
• 7 Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Léger D, Linkowski P ,. et al . Depression and sleep disorders: Clinical relevance, economic burden and pharmacological treatment.  Neuropsychobiology. 2000;  42 107-119
• 8 Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance.  Pharmacopsychiatry. 2002;  35 101-108
• 9 Buysse D -J, Hall M, Begley A, Cherry C -R, Houck P -R, Land S ,. et al . Sleep and treatment response in depression: new findings using power spectral analysis.  Psychiat Res. 2001;  103 51-67
• 10 Frieboes R -M, Sonntag A, Yassouridis A, Eap C -B, Baumann P, Steiger A. Clinical outcome after Trimipramine in patients with delusional depression - a pilot sudy.  Pharmacopsychiatry. 2003;  36 12-17
• 11 Gilbert D -J, Meliska C -J, Welser R, Estes S -L. Depression, personality, and gender influence EEG, cortisol, beta-endorphin, heart rate, and subjective responses to smoking multiple cigarettes.  Personal Ind Differ. 1994;  16 247-264
• 12 Giles D -E, Jarrett R -B, Roffwarg H -P, Rush A -J. Reduced rapid eye movement latency. A predictor of recurrence in depression.  Neuropsychopharmacol. 1987;  1 51-59
• 13 Gillin J C, Sutton L, Ruiz C. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group.  Biol Psychiatry. 1991;  30 157-69
• 14 Guzmán-Marín R, Alam N, Mihailescu S, Szymusiak R, McGinty D, Drucker-Colin R. Subcutaneous administration of nicotine changes dorsal raphe serotonergic neurons discharge rate during REM sleep.  Brain Res. 2001;  888 321-325
• 15 Hasler G, Schnyder U, Klaghofer R, Angst J. Treatment of depressive disorders with and without medication - A naturalistic study.  Pharmacopsychiatry. 2002;  35 235-238
• 16 Jamner L -D, Shapiro D, Jarvik M -E. Nicotine reduces the frequency of anger reports in smokers and nonsmokers with high but not low hostility: an ambulatory study.  Exp Clin Psychopharmacol. 1999;  7 454-463
• 17 Janson A -M, Fuxe K, Agnati L -F, Jansson A, Bjelke B, Sundstrom E ,. et al . Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat.  Prog Brain Res. 1989;  79 257-265
• 18 Leibenluft E, Wehr T -A. Is sleep deprivation useful in the treatment of depression?.  Am J Psych. 1992;  149 159-168
• 19 Marks M -J, Burch J -B, Collins A -C. Effects of chronic nicotine infusion on tolerance development and cholinergic receptors.  J Pharmacol Exp Ther. 1983;  226 806-816
• 20 Marks M -J, Pauly J -R, Gross S -D, Deneris E -S, Hermans-Borgmeyer I, Heinemann F. et al . Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment.  J Neurosci. 1992;  12 2765-2784
• 21 McGinty D -J, Harper R -M. Dorsal raphe neurons: depression of firing during sleep in cats.  Brain Res. 1976;  101 569-575
• 22 Mihailescu S, Drucker-Colín R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders.  Arch Med Res. 2000;  31 131-144
• 23 Mihailescu S, Guzmán-Marín R, Drucker-Colín R. Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons.  Eur Neuro-psychopharmacol. 2001;  11 359-366
• 24 Pomerleau C -S, Pomerleau O -F. Euphoriant effects of nicotine in smokers.  Psychopharmacol. 1992;  108 460-465
• 25 Rechtschaffen A, Kales A -A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington; Public Health Service 1968
• 26 Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Rüther E ,. et al . Trimipramine in primary insomnia: Results of a polysomnographic double-blind controlled study.  Pharmacopsychiatry. 2002;  35 165-174
• 27 Rush A -J, Erman M -K, Giles D -E, Schlesser M -A, Carpenter G, Vasavada N ,. et al . Polysomnographic findings in recently drug-free and clinically remitted depressed patients.  Arch Gen Psychiat. 1986;  43 878-884
• 28 Salín-Pascual R -J, de la Fuente J -R, Galicia-Polo L, Drucker-Colín R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients.  Psychopharmacol. 1995;  121 476-479
• 29 Salín-Pascual R -J, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression.  NeuroReport. 1998;  9 57-60
• 30 Schwartz R, Kellar K. In vivo regulation of [3H] acetylcholine recognition sites in brain by nicotinic cholinergic drugs.  J Neurochem.. 1985;  45 211-219
• 31 Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G. et al . The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression.  J Affect Disorders. 1998;  49 211-219
• 32 Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of cathecolamine metabolites predict the response to sulpride or fluvoxamine in major depression.  Pharmacopsychiatry. 2002;  35 175-181
• 33 Van den Hoofdakker R -H, Beersma D -G-M. On the contribution of sleep wake physiology to the explanation and the treatment of depression.  Acta Psychiat Scand. 1988;  S341 53-71
• 34 Vázquez J, Guzmán-Marín R, Salín-Pascual R -J, Drucker-Colín R. Transdermal nicotine on sleep and PGO spikes.  Brain Res. 1996;  737 317-320
• 35 Velázquez-Moctezuma J, Gillin J -C, Shiromani P -J. The effects of specific M₁ and M₂ receptor agonists on REM sleep generation.  Brain Res. 1989;  503 128-131
• 36 Velázquez-Moctezuma J, Shalauta M -D, Gillin J -C, Shiromani P -J. Microinjections of nicotine in the medial pontine reticular formation elicits REM sleep.  Neurosci Lett. 1990;  115 265-268
• 37 Warburton D -M. Smoking within reason.  J Smoking Rel Disorders. 1992;  3 55-59